The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Using BM and PET/CT to assess MRD status in myeloma & lymphoma patients post-CAR-T therapy
Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, discusses using a combination of bone marrow (BM) and PET/CT to assess measurable residual disease (MRD) status after CAR-T therapy for patients with multiple myeloma (MM). In this study, patients that were MRD negative for both BM and PET had the longest PFS at one month. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
